John Kaczmar, MD

Hollings Cancer Center
Charleston, SC

Disclosures:

• Employment: none
• Compensation: none
• Ownership: none
• Leadership: none

Presentation(s):

• 3627 - Safety and Activity Profile of Fianlimab (Anti-LAG-3) in Combination With Cemiplimab (Anti-PD-1) and Cemiplimab Monotherapy in Recurrent and/or Metastatic HNSCC

  Wednesday, October 2, 2024
  10:30 AM – 11:45 AM ET